A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

G.R. Blumenschein; E.F. Smit; D. Planchard; D.W. Kim; J. Cadranel; T. De Pas; F. Dunphy; K. Udud; M.J. Ahn; N.H. Hanna; J.H. Kim; J. Mazieres; S.W. Kim; P. Baas; E. Rappold; S. Redhu; A. Puski; F.S. Wu; P.A. Janne

doi:10.1093/annonc/mdv072

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

G.R. Blumenschein, E.F. Smit, D. Planchard, D.W. Kim, J. Cadranel, T. De Pas, F. Dunphy, K. Udud, M.J. Ahn, N.H. Hanna, J.H. Kim, J. Mazieres, S.W. Kim, P. Baas, E. Rappold, S. Redhu, A. Puski, F.S. Wu, P.A. Janne

Pulmonary medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	894-901
Journal	Annals of Oncology
Volume	26
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdv072
Publication status	Published - 2015

Access to Document

10.1093/annonc/mdv072

Cite this

Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D. W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M. J., Hanna, N. H., Kim, J. H., Mazieres, J., Kim, S. W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., & Janne, P. A. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 26(5), 894-901. https://doi.org/10.1093/annonc/mdv072

@article{9866d163146f469096b1510657283a42,

title = "A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)",

author = "G.R. Blumenschein and E.F. Smit and D. Planchard and D.W. Kim and J. Cadranel and {De Pas}, T. and F. Dunphy and K. Udud and M.J. Ahn and N.H. Hanna and J.H. Kim and J. Mazieres and S.W. Kim and P. Baas and E. Rappold and S. Redhu and A. Puski and F.S. Wu and P.A. Janne",

year = "2015",

doi = "10.1093/annonc/mdv072",

language = "Undefined/Unknown",

volume = "26",

pages = "894--901",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "5",

}

Blumenschein, GR, Smit, EF, Planchard, D, Kim, DW, Cadranel, J, De Pas, T, Dunphy, F, Udud, K, Ahn, MJ, Hanna, NH, Kim, JH, Mazieres, J, Kim, SW, Baas, P, Rappold, E, Redhu, S, Puski, A, Wu, FS & Janne, PA 2015, 'A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)', Annals of Oncology, vol. 26, no. 5, pp. 894-901. https://doi.org/10.1093/annonc/mdv072

TY - JOUR

T1 - A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

AU - Blumenschein, G.R.

AU - Smit, E.F.

AU - Planchard, D.

AU - Kim, D.W.

AU - Cadranel, J.

AU - De Pas, T.

AU - Dunphy, F.

AU - Udud, K.

AU - Ahn, M.J.

AU - Hanna, N.H.

AU - Kim, J.H.

AU - Mazieres, J.

AU - Kim, S.W.

AU - Baas, P.

AU - Rappold, E.

AU - Redhu, S.

AU - Puski, A.

AU - Wu, F.S.

AU - Janne, P.A.

PY - 2015

Y1 - 2015

U2 - 10.1093/annonc/mdv072

DO - 10.1093/annonc/mdv072

M3 - Article

C2 - 25722381

VL - 26

SP - 894

EP - 901

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -